top of page
BP Bio.png


Translational Medicine (Clinical Development and Regulatory Strategy)

Bill Pullman, MB MS BMedSc PhD FRACP, has more than 35 years of experience, spanning the fields of Clinical Practice and Pharmaceutical Research and Development with “small” molecular and biologic (protein, antibody) therapeutics. He has played key roles in developing and progressing a significant number of innovative medicines through Regulatory approval in the US and EU (NDA and MAA) and onto market. Additionally, he has experience in Medical Affairs and Regulatory Approval in the Asia Pacific region (Australia, New Zealand and Japan) and has many successful IND’s to his credit.

Previously serving in roles for small to mid-sized Biotech companies, including Chief Scientific Officer (Proximagen LLC, Upsher-Smith Pharmaceuticals), Chief Medical Officer (Cubist) or Chief Development Officer (Dyax, TransForm), Bill has led strategic direction as well as operational and tactical execution for clinical, regulatory and scientific affairs for novel molecular entities as well as drug repurposing efforts. His contributions to Drug Development include pipeline selection and enhancement, translational medicine innovations including biomarker application, novel early and late phase clinical trial designs, medical affairs, and regulatory interactions.

Prior to his Biotech experience, Bill worked in a variety of roles for big Pharma companies including Pfizer, Lilly, Aventis, Sanofi-Aventis specializing in Clinical Pharmacology, Clinical Research and Medical Affairs. He completed his primary medical training at the University of Western Australia and is a fellow of the Royal Australian College of Physicians. He also received a Ph.D. in Medicine and Clinical Science (Immunology) from the Australian National University.

bottom of page